Summit Trail Advisors’s Integra LifeSciences IART Stock Holding History

Summit Trail Advisors’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38M	Sell	76,794 -44,822	-37%	-$627K	0.02%	841
2026 Q1	$1.15M	Buy	121,616 +52,297	+75%	+$574K	0.02%	872
2025 Q4	$861K	Buy	69,319 +17,952	+35%	+$239K	0.01%	891
2025 Q3	$736K	Sell	51,367 -41,577	-45%	-$570K	0.01%	966
2025 Q2	$1.14M	Buy	+92,944	New	+$1.35M	0.02%	427
2018 Q1	–	Sell	-5	Closed	–	–	1001
2017 Q4	$0	Buy	+5	New	+$245	﹤0.01%	2026

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Summit Trail Advisors's IART Position: Q2 2026 in Review

Summit Trail Advisors reduced its Integra LifeSciences (IART) stake by 37% in Q2 2026, selling an estimated $627K and leaving 76,794 shares worth $1.38M. The position accounts for 0.02% of the portfolio, ranked #841.

Summit Trail Advisors first reported a position in IART in Q4 2017 and has held it in 6 quarters since. 213 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Summit Trail Advisors held 76,794 shares of Integra LifeSciences worth $1.38M as of Q2 2026.
Summit Trail Advisors sold 44,822 Integra LifeSciences shares in Q2 2026, an estimated $627K.
Integra LifeSciences made up 0.02% of Summit Trail Advisors's portfolio in Q2 2026, its #841 holding.
Summit Trail Advisors first reported a position in Integra LifeSciences in Q4 2017 and has held it in 6 quarters since.
213 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.